Find and Pitch Jounalists, Get Your Story Covered

Tags: Business & Regulation Power cyclin-dependant kinase-like deficiency disorder ganaxolone Marinus Pharmaceuticals

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more - 11 days ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 18 days ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 25 days ago STAT+: Catalent tries to reassure customers about its deal with Novo Holdings - 25 days ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 2 months ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 2 months ago STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more - 3 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 4 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 4 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 5 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 7 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a Novo Nordisk deal, a Regeneron setback, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more - 9 months ago STAT+: Major generic maker Aurobindo cuts production at a key plant amid concerns over shortages - 9 months ago STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more - 9 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - 9 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 10 months ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 11 months ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - 11 months ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - 11 months ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - 11 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 11 months ago STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade - 12 months ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - 12 months ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - about 1 year ago STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin - about 1 year ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - about 1 year ago STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket - about 1 year ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - about 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - about 1 year ago STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro - about 1 year ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - about 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - about 1 year ago STAT+: Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses - about 1 year ago STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing - about 1 year ago
2	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Sanofi Jumps Into Radiopharmaceuticals, Paying €100M for Therapy That Could Rival a Novartis Drug - 2 months ago Otsuka Commits $800M in M&A Deal Bringing a Phase 3-Ready Metabolic Disorder Drug - 4 months ago Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds - 7 months ago Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition - 7 months ago Novartis Pays $150M to Nab a Phase 3-Ready Protein Degrader for Prostate Cancer - 7 months ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	BioMarin’s big day today - 2 months ago STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor - 7 months ago STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill - 7 months ago STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation - about 1 year ago
4	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - 3 months ago Johnson & Johnson antiviral pill for dengue shows early efficacy - about 1 year ago
5	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	In a Duchenne market beset by problems, Capricor data marks a bright spot - 3 months ago After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners - 5 months ago To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach - 8 months ago
6	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 5 months ago Astellas’ science chief on the leap into new technologies - 9 months ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - about 1 year ago
7	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells - 7 months ago STAT+: Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion - 8 months ago
8	Eric Volkman Motley Fool Investing guidance to make the world smarter, happier, richer. InvestingFinancial Guidance	Why Amarin Stock Was Rocketing Higher on Wednesday - 8 months ago
9	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Merck’s next big thing is (probably) on the way - 8 months ago BioMarin appeases an activist - 11 months ago Medtronic isn’t afraid of Wegovy’s potential to disrupt - 12 months ago BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge - about 1 year ago Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis - about 1 year ago
10	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Marina Passarell - 8 months ago

Journalists covering Marinus Pharmaceuticals